Results 121 to 130 of about 11,119 (206)

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos   +9 more
wiley   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla   +33 more
wiley   +1 more source

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age [PDF]

open access: yes, 2017
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1.
Giovanni Corsello   +4 more
core  

Exome Profiling Suggests Combined Effect of Myeloperoxidase, Toll-Like Receptors, and Metallopeptidase in Hidradenitis Suppurativa

open access: yesBiomedicines
Background: Hidradenitis suppurativa, also called acne inversa, is a chronic skin inflammatory condition involving hair follicles, sebaceous glands, and apocrine glands. Symptoms can be variable in intensity, ranging from mild to severe. The exact causes
Alessia Azzarà   +3 more
doaj   +1 more source

Novel Clinical and Histological Insights into Cutaneous Kikuchi‐Fujimoto Disease and Kikuchi Disease‐Like Inflammatory Pattern (KLIP)

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Magí Brufau‐Cochs   +7 more
wiley   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster   +68 more
wiley   +1 more source

Building the foundations for an international patient‐centred outcomes set for psoriasis: A scoping study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This scoping study refined the first patient‐centred outcome set for psoriasis, involving patient representatives and dermatologists from 22 countries. The proposal includes 18 patient‐relevant outcomes, 2 patient experiences, corresponding outcome measurement instruments and 50 case‐mix variables.
Emma Vyvey   +35 more
wiley   +1 more source

Hidradenitis suppurativa patient requiring cardiac procedure with inguinal access: Case management with ertapenem

open access: yesSAGE Open Medical Case Reports
Hidradenitis suppurativa is a chronic inflammatory skin disease that usually presents in young adults with painful abscesses in intertriginous areas.
Laurence Mainville   +2 more
doaj   +1 more source

Modestly Increased Incidence of Irritable Bowel Syndrome in Hidradenitis Suppurativa: A Retrospective Cohort Study Using TriNetX

open access: yes
International Journal of Dermatology, EarlyView.
Sahithi Talasila   +4 more
wiley   +1 more source

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy